Published in Lab Business Week, September 16th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Repligen Corporation.
Report 1: Repligen Corporation (NASDAQ:RGEN) announced that it has expanded its longstanding relationship with Applied Biosystems by entering into a four-year supply agreement for recombinant Protein A. Repligen is the world's leading supplier of recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies, the largest and fastest growing class of drug in the biopharmaceutical industry.
"We are very pleased to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.